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 Abstract 
 
Purpose of review: Acute optic neuritis (ON) is a common clinical problem, 
requiring a structured assessment to guide management and prevent visual loss. 
The optic nerve is the most accessible part of the central nervous system (CNS), 
so ON also represents an important paradigm to help decipher mechanisms of 
damage and recovery in the CNS. Important developments include the advent of 
optical coherence tomography (OCT) as a biomarker of CNS axonal loss, the 
discovery of new pathological antibodies, notably against aquaporin-4 and, more 
recently, myelin oligodendrocyte protein, and emerging evidence for sodium 
channel blockade as a novel therapeutic approach to address energy failure in 
neuroinflammatory disease. 
Recent findings: We will present a practical approach to assessment of ON, 
highlighting the role of OCT, when to test for new antibodies and the results of 
recent trials of sodium channel blockers. 
Summary: ON remains a clinical diagnosis; increasingly OCT is a key ancillary 
investigation. Patients with “typical” ON, commonly a first presentation of 
multiple sclerosis, must be distinguished from “atypical” ON, who require testing 
for new pathological antibodies and require more aggressive targeted treatment. 
Sodium channel blockade is an emerging and novel potential therapeutic pathway 
in neuroinflammatory disease. 
 
 
 
 Introduction 
 
Acute optic neuritis (ON) is relatively common with an estimated lifetime 
prevalence of 0.6/1000 [1], and age- and sex-adjusted incidence of 1-5/100 000 
[1, 2]. ON most frequently affects young Caucasian women; the mean age of onset 
is 31-32 years [3, 4]. Patients may present to ophthalmologists, neurologists, 
emergency physicians or general practitioners, so knowledge of the condition is 
necessary for a wide range of clinicians. The presenting symptoms are readily 
recognisable and diagnosis is essentially clinical. In most patients, the pathology 
is demyelination of the optic nerve, which may reflect a first relapse of multiple 
sclerosis (MS), if there is additional clinical or radiological evidence of brain 
lesions fulfilling diagnostic criteria [5], or a clinically isolated syndrome 
suggestive of MS, if no evidence of intracranial involvement is present.  In these 
patients with “typical” demyelinating ON (T-ON), spontaneous visual recovery is 
expected, and visual prognosis is good in 90-95% of cases [6]. In a smaller 
proportion of patients, ON occurs with a cause other than typical demyelination, 
usually an alternative inflammatory or infective disease. These patients exhibit 
“red flags” for an more aggressive aetiology, generally do not recover without 
directed treatment and are termed atypical ON (A-ON) in this review. 
Distinguishing T-ON from A-ON is critical to prevent permanent visual loss. In this 
review, we will describe a structured approach to the assessment of a patient with 
ON with a focus on recent developments, including the expanding role of optical 
coherence tomography (OCT), identification of new pathogenic antibodies 
implicated in cases of A-ON, and the insights that ON has provided into pathology 
of central nervous system (CNS) disorders including an emerging role for energy 
failure in neuroinflammatory disease and sodium channel blockade as a potential 
new therapeutic strategy. 
 
Clinical features of T-ON 
 
An attack of ON generally begins with periocular pain characteristically as worse 
on eye movements. Concurrent with pain onset, or following within a few days, 
visual loss occurs, ranging from mild blurring to loss of perception of light. There 
is usually dyschromatopsia. Associated positive visual phenomena, such as flashes 
of light on eye movements (termed phosphenes or photopsia) have been 
described. The presence of a relative afferent pupillary defect is a key clinical 
finding; patients with subclinical demyelination in the fellow eye or ipsilateral 
mild optic neuritis may not exhibit this sign. The optic disc is usually normal but 
is swollen in a third of patients [3] (termed papillitis rather than papilloedema); 
haemorrhages and exudates are unusual in T-ON but are more commonly seen in 
A-ON. In patients with subtle visual loss, acuities may be preserved but deficits of 
colour vision or low contrast acuity are evident in the vast majority [3]. Seventy 
nine percent of patients with T-ON begin to improve by three weeks and 93% by 
five weeks [7]. Vision returns to near normal, in terms of measured acuity [7], but 
patients often report their eyesight is not quite as good as before [8]; colours often 
appear washed out and residual visual problems may still impact on quality of life 
[9]. Uhthoff’s and Pulfrich’s phenomena may be noted around the time of visual 
recovery (respectively, transient worsening of vision with elevation of body 
temperature, for example, after a hot bath or exercise [10], and difficulty judging 
the trajectory of a moving object, for example, a tennis ball, despite good visual 
acuity [11]). 
 
Clinical features of A-ON 
 
Many of the initial features of A-ON are the same as T-ON but painless or very 
painful onset is more common (absence of pain was only seen in 8% of people 
with T-ON in the pivotal Optic Neuritis Treatment Trial [3]). Severe visual loss 
with haemorrhages and exudates on fundoscopy are red flags for A-ON, especially 
in non-Caucasian patients, in whom alternative inflammatory disorders such as 
sarcoidosis and lupus erythematosis (SLE) have a higher prevalence. Progression 
of visual loss beyond three weeks of onset, or failure of significant recovery at six 
weeks, suggest A-ON. The clinical features that help identify patients with A-ON 
are summarised in Table 1, together with some of the more common alternative 
causes to consider. Atypical inflammatory causes include neuromyelitis optica 
spectrum disorder with anti-aquaporin-4 (AQ4) or anti-myelin oligodendrocyte 
glycoprotein (MOG) antibodies, sarcoidosis, SLE, Behcet’s disease or 
granulomatosis with polyangiitis (GPA formerly known as Wegener’s 
granulomatosis), and are important to identify because early and aggressive 
immunosuppression, initially with steroids, can prevent permanent visual loss. 
Optic atrophy evident before six weeks can suggest optic nerve compression, 
metabolic or hereditary disorders (Leber’s hereditary optic neuropathy (LHON) 
or autosomal dominant optic atrophy). There are a number of infective causes that 
also require targeted treatment (for example, human immunodeficiency virus 
(HIV), tuberculosis (TB), syphilis and Bartonella henselae “cat scratch disease”; 
look for a macular star of associated neuroretinitis). Nutritional causes of optic 
neuropathy include tobacco-alcohol amblyopia, but the history is often slower 
than T-ON and painless. Ischaemic optic neuropathy tends to occur in patients 
with hypermetropic discs; this is usually painless (unless there is associated 
temporal arteritis), optic nerve swelling is universal during the acute phase and 
an altitudinal visual field defect is typical (but can also occur in T-ON). 
 
 Investigations 
 
T-ON is a clinical diagnosis and ancillary investigations are not mandatory if there 
are no red flags to suggest A-ON. OCT is emerging as a useful ancillary 
investigation and assessment of retinal nerve fibre layer (RNFL) thickness, with a 
peripapillary ring scan, and macular volume, were advocated in a recent expert 
consensus review [12]. OCT has identified additional pathological features, such 
as macular cystic changes in some patients [13]; the significance and nature of 
their pathophysiology is debated and a topic of further research. Cranial magnetic 
resonance imaging (MRI) is helpful to stratify risk of subsequent MS in clinically 
isolated T-ON- if the patient wishes to know- and to confirm the diagnosis of MS 
in people with a history of previous neurological episodes. High signal and 
contrast enhancement in the optic nerves are commonly seen on these scans in 
acute T-ON [14, 15]. In patients with isolated T-ON, subsequent risk of MS is 
dependent on length of follow-up and is approximately 25% at 15 years with a 
normal baseline cranial MRI and 72% if even a single demyelinating brain lesion 
was present [16]; risk rises with number of intracranial lesions. Risk rises with 
presence of oligoclonal bands in the cerebrospinal fluid too [17], but this is not 
routinely performed in T-ON. 
 
The situation is different in A-ON. If any red flags are present to indicate A-ON, 
patients require early and more extensive investigation, described in Table 2. 
 
Management 
 
In many patients with T-ON, no treatment is usually required. Early follow-up is 
important to ensure visual recovery. Methylprednisolone reduces the duration of 
an attack of T-ON but does not appear to improve visual outcome [18]. Prednisone 
was ineffective and, surprisingly, increased recurrence risk in the Optic Neuritis 
Treatment Trial (ONTT), the pivotal study that also yielded much of the natural 
history data reported above [18]. The benefits and risks of steroids versus no 
treatment may be discussed with patients with T-ON; patients with severe pain or 
visual loss, or coexistent fellow eye pathology, may have most to gain. Short-term 
side effects of steroids include insomnia, mood disturbance and, rarely, aseptic 
necrosis of the femoral head. If a patient opts for steroids, clinical practice is 
extrapolated from MS studies showing equivalence of using intravenous or oral 
steroids in MS relapses [19]; either oral methylprednisolone 500mg for 5 days or 
intravenous methylprednisolone 1g for 3 days may be used depending on local 
preference [20]. There is at present no available treatment for patients with T-ON 
who fail to recover. Biomarkers to identify these patients early are required; 
cerebrospinal fluid neurofilament light chains have been proposed [21], and 
research in this area is ongoing.  
 Patients with A-ON require targeted treatment to prevent visual loss. In particular, 
people with an inflammatory cause of A-ON require prolonged courses of steroids; 
initial intravenous methylprednisolone induction is followed by oral prednisolone 
tapered over several months. The duration of therapy and use of alternative 
steroid-sparing agents depends on subsequent clinical course and the underlying 
cause. Plasma exchange has been used in cases with severe visual loss 
unresponsive to steroids of varying aetiologies [22]. 
 
Recent developments and future directions: the eye as a window to the brain 
 
The optic nerve represents the most accessible part of the CNS, may be viewed 
directly using the ophthalmoscope and, now, the RNFL axons can be measured 
accurately using OCT. This accessibility and the fact that visual function can be 
measured objectively make ON an important model for research into CNS 
inflammatory disease. Study of patients with ON has led to advances in 
understanding of the pathophysiology of CNS inflammatory disease, for example, 
blood-brain barrier changes in association with conversion from ON to MS [23], 
trans-synaptic degeneration [24], relationships between demyelination and 
deficits in specific visual modalities [25] and the role of cortical plasticity in 
recovery [26, 27]. OCT measures such as RNFL thickness are now recommended 
as a surrogate marker for axonal loss in clinical trials in MS [28, 29] and appear to 
correlate with brain atrophy, especially within grey matter [30]. A recent multi-
centre study showed that RNFL thinning correlated with disability in MS [31], 
implying that the axonal loss measurable with OCT is clinically relevant, and 
validating its role as a surrogate marker of the pathology underpinning MS 
progression. Interestingly, RNFL thinning appears to progress in MS but not NMO 
[32], another fascinating difference between these contrasting 
neuroinflammatory diseases. The importance of OCT is likely to continue to grow 
because, despite rapid advances in relapsing-remitting MS therapeutics, 
treatment for the progressive phase remains the greatest challenge in the field. ON 
research therefore remains at the front line in the battle against 
neurodegenerative disease.  
 
Blockade of sodium channels has been proposed as a novel therapeutic strategy 
to address axonal loss in secondary progressive MS. A hypothesis of energy failure 
was developed from animal models of experimental allergic encephalomyelitis 
[33, 34]; subsequent intra-axonal sodium accumulation is thought to lead to 
reversal of the sodium-calcium exchange pump and result in lethal accumulation 
of intra-axonal calcium [35, 36]. Phenytoin, a sodium channel blocker, reduced 
RNFL loss by 30% in a recent trial in ON patients [37], supporting proof of 
principle, although no effect on visual acuity was detectable. Similar results were 
obtained from a previous trial of memantine [38]. Alternative strategies of ion 
channel blockade using amiloride are also under investigation [39]. A differing 
approach is based upon a proposed neurotrophic role for erythropoietin; one 
phase II trial was encouraging [40] but another was negative [41]. A further trial 
of erythropoietin is underway [42]; The role of vitamin D in neuroinflammatory 
disease is debated; dynamic associations with RNFL thickness have been observed 
[43] but a recent study showed no association with disease severity [44]. 
 
Another key development has been the widening spectrum of antibody-mediated 
neuroinflammatory disease affecting the optic nerve, starting with the discovery 
of AQ4 antibodies [45, 46] in neuromyelitis optica (NMO). NMO restricted to the 
optic nerve is now a well established disease phenotype [47-49] and requires 
early and aggressive immunosuppression. The discovery of the AQ4 antibody was 
followed by the identification of antibodies to myelin oligodendrocyte protein 
(MOG) [50], found in 25-33% of AQ4 negative patients. These patients have a 
similar NMO phenotype [51, 52] but also some important differences to AQ4 
patients, such as a higher frequency in children [53], a male preponderance, a 
monophasic course with fewer relapses [52] and more frequent involvement of 
the anterior, rather than posterior, visual pathways [54]. It appears likely that 
discovery of other antibodies will follow and the spectrum of A-ON will continue 
to expand, with important consequences for our understanding of CNS 
inflammatory disease. 
 
Conclusion 
 
In summary, accurate diagnosis of ON is important, especially the recognition of 
any atypical features, in order to guide management and optimise visual 
prognosis. Moreover, ON offers a window into CNS pathophysiology that is 
starting to be exploited to address key therapeutic challenges in areas such as 
progressive MS.  
Key points 
 
 ON is a clinical diagnosis; in typical cases, no diagnostic investigations are 
routinely required although MRI is offered to help stratify the risk of future 
conversion to MS. 
 The most important aspect of assessment is to identify any atypical 
features; these patients require further investigation and targeted 
management. 
 ON offers a window into the pathophysiology of neuroinflammatory 
disease. 
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Table 1 Red flags that can indicate a case of A-ON and possible alternative 
diagnoses 
 Clinical feature 
 
Comments Possible alternative diagnoses 
History: 
Lack of pain Seen in 8% of 
patients with 
T-ON 
Optic nerve compression, 
hereditary (e.g. LHON), 
nutritional, maculopathies 
Severe or prolonged pain Wakes the 
patient up at 
night 
Inflammatory or granulomatous 
causes e.g. AQ4, sarcoid 
Severe visual loss in non-
Caucasian 
<6/60 SLE, sarcoid, Behcet’s disease,  
Prolonged deterioration 
>2-3 weeks  
 Infectious (e.g. HIV, syphilis, Lyme, 
Bartonella, TB), nutritional, 
compression, alternative 
inflammatory (AQ4, MOG, SLE, 
sarcoid, Behcet’s, GPA ), CRION 
Bilateral simultaneous 
ON 
 AQ4, MOG, infectious 
History of cancer  Compression, paraneoplastic 
retinopathy 
Examination: 
Visual acuity  <6/60 Alternative inflammatory, 
infectious 
Fundoscopy: optic 
atrophy at presentation 
 Compression, metabolic 
Fundoscopy: retinal 
abnormalities 
Macular star 
and papillitis 
Neuroretinitis (Bartonella, Lyme, 
syphilis) 
Follow-up:   
Lack of recovery at 6 
weeks 
Beware ON in 
an amblyopic 
eye as an 
alternative 
cause of 
apparent poor 
recovery 
Compression, LHON, nutritional, 
atypical inflammatory (AQ4, MOG, 
sarcoid, SLE, Behcet’s, GPA) 
Relapse on steroid 
withdrawal 
 CRION, atypical inflammatory 
A-ON- atypical optic neuritis; AQ4- aquaporin-4 antibody related optic neuritis; CRION- 
chronic relapsing inflammatory optic neuritis; GPA- Granulomatosis with polyangiitis; 
HIV- human immunodeficiency virus; LHON- Leber’s hereditary optic neuropathy, MOG- 
myelin oligodendrocyte glycoprotein antibody-related optic neuritis; SLE- systemic lupus 
erythematosis; T-ON- typical optic neuritis  
 
 
 
Table 2 Investigations to consider in cases of A-ON 
 
Investigation Looking for… Comments 
Cranial MRI Intracranial 
inflammation in sarcoid, 
SLE, AQ4, MOG, etc 
Also useful in T-ON to 
diagnose or stratify risk 
of MS 
Orbital MRI Optic nerve 
compression- mostly 
painless (except 
aneurysm and 
mucocoele) 
Optic nerve sheath 
meningioma, optic nerve 
glioma, metastases, 
lymphoma, mucocoele, 
aneurysms 
Cerebrospinal fluid Elevated cell count and 
protein in AQ4, 
sarcoidosis, SLE, MOG, 
Behcet’s, GPA, infections 
A low grade 
inflammatory response 
(CSF WCC<50 may be 
seen in MS) 
AQ4 antibodies NMO spectrum disorder Guarded visual 
prognosis 
Anti-MOG antibodies NMO spectrum disorder Perform if AQ-4 
negative; may be milder 
phenotype than AQ4 
Other blood tests: serum 
ACE, ANA, ANCA 
Sarcoid, SLE, GPA  Especially severe visual 
loss in non-Caucasian 
patients 
Chest radiograph Sarcoid, TB  
Infectious serology: HIV, 
VDRL, Lyme, Bartonella, 
TB 
Bilateral disease, other 
neurological signs, 
neuroretinitis  
 
Genetics LHON, autosomal 
dominant optic atrophy 
mutations  
 
ACE- angiotensin converting enzyme; A-ON- atypical optic neuritis; ANCA- anti-
neutrophil cytoplasmic antibody; AQ4- aquaporin-4 antibody related optic neuritis; CSF- 
cerebrospinal fluid; GPA- Granulomatosis with polyangiitis; LHON- Leber’s hereditary 
optic neuropathy; MOG- myelin oligodendrocyte glycoprotein antibody-related optic 
neuritis; MRI- magnetic resonance imaging; MS- multiple sclerosis; NMO- neuromyelitis 
optica; OPA- opSLE- systemic lupus erythematosis; T-ON- typical optic neuritis; VDRL- 
venereal disease research laboratory test for syphilis; WCC- white cell count 
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